In-Cell-Art announces the publication in Nature Biomedical Engineering of a Nanotaxi® for messenger RNA vaccin

16 May 2019

In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to treat acquired or inherited diseases, announces today that ICA and international academic researchers published in the journal Nature Biomedical Engineering*  the characterization of the mechanism by which a Nanotaxi® allows in non-human primate efficient delivery of messenger RNA molecules in cells of interest for the implementation of a robust immune response.

Read the full press release